Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Catalyst Pharmaceuticals (NASDAQ: CPRX) has been ranked 452nd on the 2024 Deloitte Technology Fast 500™ list, showcasing North America's fastest-growing companies across technology, media, telecommunications, life sciences, fintech, and energy tech sectors. The company achieved 234% revenue growth between 2020 and 2023, attributed to operational excellence and strong commercial execution.
The 30th annual rankings featured companies with growth rates ranging from 201% to 153,625%, with an average of 1,981% and a median of 460%. Notably, this year marked a significant breakthrough in private company performance, with the software and fintech sectors showing particularly strong representation.
Catalyst Pharmaceuticals (NASDAQ: CPRX) è stata classificata al 452° posto nella lista 2024 del Deloitte Technology Fast 500™, che mette in evidenza le aziende in più rapida crescita del Nord America nei settori della tecnologia, dei media, delle telecomunicazioni, delle scienze della vita, della fintech e della tecnologia energetica. L'azienda ha registrato una crescita del fatturato del 234% tra il 2020 e il 2023, dovuta all'eccellenza operativa e a una forte esecuzione commerciale.
Il trentesimo ranking annuale ha presentato aziende con tassi di crescita che vanno dal 201% al 153.625%, con una media dell'1.981% e una mediana del 460%. È interessante notare che quest'anno ha segnato una significativa avanzata nella performance delle aziende private, con i settori del software e della fintech che mostrano una rappresentanza particolarmente forte.
Catalyst Pharmaceuticals (NASDAQ: CPRX) ha sido clasificada en el puesto 452 en la lista 2024 del Deloitte Technology Fast 500™, que destaca a las empresas de más rápido crecimiento en América del Norte en los sectores de tecnología, medios, telecomunicaciones, ciencias de la vida, fintech y tecnología energética. La empresa logró un crecimiento de ingresos del 234% entre 2020 y 2023, lo que se atribuye a la excelencia operativa y a una sólida ejecución comercial.
El trigésimo ranking anual presentó empresas con tasas de crecimiento que oscilan entre el 201% y el 153,625%, con un promedio del 1,981% y una mediana del 460%. Cabe destacar que este año marcó un avance significativo en el rendimiento de las empresas privadas, con los sectores de software y fintech mostrando una representación particularmente fuerte.
캐탈리스트 제약(Catalyst Pharmaceuticals) (NASDAQ: CPRX)는 2024 딜로이트 테크놀로지 패스트 500™ 목록에서 452위로 선정되었습니다. 이 목록은 북미의 가장 빠르게 성장하는 기업들을 기술, 미디어, 통신, 생명과학, 핀테크 및 에너지 기술 부문에서 소개합니다. 이 회사는 2020년부터 2023년까지 234%의 매출 성장을 달성했으며, 이는 운영 우수성과 강력한 상업 실행 덕분입니다.
30번째 연례 순위에서는 성장률이 201%에서 153,625%에 이르는 기업들이 소개되었으며, 평균 성장률은 1,981%, 중앙값은 460%입니다. 특히, 올해는 민간 기업의 성과에서 중요한 돌파구를 나타내었으며, 소프트웨어 및 핀테크 부문이 특히 강한 대표성을 보였습니다.
Catalyst Pharmaceuticals (NASDAQ: CPRX) a été classée 452ème sur la liste 2024 du Deloitte Technology Fast 500™, mettant en avant les entreprises à la croissance la plus rapide en Amérique du Nord dans les secteurs de la technologie, des médias, des télécommunications, des sciences de la vie, de la fintech et des technologies énergétiques. L'entreprise a réalisé une croissance de chiffre d'affaires de 234% entre 2020 et 2023, grâce à une excellence opérationnelle et à une exécution commerciale solide.
Le 30ème classement annuel a présenté des entreprises avec des taux de croissance allant de 201% à 153.625%, avec une moyenne de 1.981% et une médiane de 460%. Il est à noter que cette année a marqué une avancée significative dans la performance des entreprises privées, les secteurs des logiciels et de la fintech affichant une représentation particulièrement forte.
Catalyst Pharmaceuticals (NASDAQ: CPRX) wurde auf den 452. Platz der Deloitte Technology Fast 500™ Liste 2024 eingestuft, die die am schnellsten wachsenden Unternehmen Nordamerikas in den Bereichen Technologie, Medien, Telekommunikation, Lebenswissenschaften, Fintech und Energietechnologie präsentiert. Das Unternehmen erzielte zwischen 2020 und 2023 ein Umsatzwachstum von 234%, was auf betriebliche Exzellenz und starke kommerzielle Umsetzung zurückzuführen ist.
Das 30. jährliche Ranking zeigte Unternehmen mit Wachstumsraten von 201% bis 153.625%, mit einem Durchschnitt von 1.981% und einem Median von 460%. Bemerkenswert ist, dass in diesem Jahr ein signifikanter Durchbruch in der Leistung privater Unternehmen zu verzeichnen war, wobei die Software- und Fintech-Sektoren besonders stark vertreten waren.
- None.
- None.
Attributes
CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Catalyst grew
Catalyst’s President and Chief Executive Officer, Richard J. Daly, credits the team’s operational excellence and strong commercial execution for the
“For 30 years we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” said Steve Fineberg, Vice Chair, U.S. technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”
“Innovation, transformation and disruption of the status quo are at the forefront for this year’s Technology Fast 500 list, and there’s no better way to celebrate 30 years of program history,” said Christie Simons, Partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s Audit & Assurance practice. “This year’s winning companies have demonstrated a continuous commitment to growth and remarkable consistency in driving forward progress. We extend our congratulations to all of this year’s winners — it’s an incredible time for innovation.”
Overall, 2024 Technology Fast 500 companies achieved revenue growth ranging from
About the 2024 Deloitte Technology Fast 500
Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
What was Catalyst Pharmaceuticals' (CPRX) revenue growth rate from 2020 to 2023?
What ranking did Catalyst Pharmaceuticals (CPRX) receive on the 2024 Deloitte Technology Fast 500 list?
What was the growth range for companies on the 2024 Deloitte Technology Fast 500 list?
What factors contributed to Catalyst Pharmaceuticals' (CPRX) growth according to their CEO?
